Insights

Strong Financial Base Genmab's substantial revenue of approximately 10 billion dollars and funding of 5.5 billion dollars position it as a financially robust company, indicating potential for partnership or investment opportunities in innovative antibody therapeutics.

Pipeline Focus Recent strategic decisions to discontinue lower-value or late-stage assets like acasunlimab highlight Genmab’s focus on high-potential, late-stage cancer therapies, offering opportunities to collaborate on cutting-edge oncology treatments.

Market Expansion With an international presence spanning North America, Europe, and Asia Pacific, Genmab offers multiple regional markets for strategic partnerships, licensing, and distribution of proprietary antibody medicines.

Innovation Leadership Genmab’s emphasis on next-generation antibody platforms and leveraging data sciences presents a key opportunity to provide complementary technologies, services, or joint development in antibody research and development.

Industry Alignment Operating in a competitive landscape alongside major biotech and pharma giants like Amgen, AbbVie, and Roche, Genmab’s focus on innovative cancer treatments makes it a strategic partner for companies seeking to expand their oncology portfolios.

Genmab Tech Stack

Genmab uses 8 technology products and services including QlikView, Ansible, SQL, and more. Explore Genmab's tech stack below.

  • QlikView
    Business Intelligence
  • Ansible
    Configuration Management
  • SQL
    Database
  • ISO/IEC 27001
    Governance, Risk And Compliance
  • Angular
    Javascript Frameworks
  • Vyond
    Marketing
  • Hootsuite
    Marketing
  • Microsoft
    Miscellaneous

Media & News

Genmab's Email Address Formats

Genmab uses at least 1 format(s):
Genmab Email FormatsExamplePercentage
F.Last@genmab.comJ.Doe@genmab.com
54%
LastFirst@genmab.comDoeJohn@genmab.com
27%
FirstL@genmab.comJohnD@genmab.com
13%
FiLast@genmab.comJoDoe@genmab.com
6%

Frequently Asked Questions

What is Genmab's phone number?

Minus sign iconPlus sign icon
You can contact Genmab's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Genmab's stock symbol?

Minus sign iconPlus sign icon
Genmab is a publicly traded company; the company's stock symbol is GMAB.

What is Genmab's official website and social media links?

Minus sign iconPlus sign icon
Genmab's official website is genmab.com and has social profiles on LinkedInCrunchbase.

How much revenue does Genmab generate?

Minus sign iconPlus sign icon
As of December 2025, Genmab's annual revenue is estimated to be $5B.

What is Genmab's SIC code NAICS code?

Minus sign iconPlus sign icon
Genmab's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Genmab have currently?

Minus sign iconPlus sign icon
As of December 2025, Genmab has approximately 2.6K employees across 6 continents, including EuropeNorth AmericaAsia. Key team members include Cmo Evp Head Of Experimental Medicine: T. A.Chief Financial Officer: A. P.Chief Of Staff: P. M.. Explore Genmab's employee directory with LeadIQ.

What industry does Genmab belong to?

Minus sign iconPlus sign icon
Genmab operates in the Biotechnology Research industry.

What technology does Genmab use?

Minus sign iconPlus sign icon
Genmab's tech stack includes QlikViewAnsibleSQLISO/IEC 27001AngularVyondHootsuiteMicrosoft.

What is Genmab's email format?

Minus sign iconPlus sign icon
Genmab's email format typically follows the pattern of F.Last@genmab.com. Find more Genmab email formats with LeadIQ.

How much funding has Genmab raised to date?

Minus sign iconPlus sign icon
As of December 2025, Genmab has raised $5.5B in funding. The last funding round occurred on Sep 29, 2025 for $5.5B.

Genmab

Biotechnology ResearchHovedstaden, Denmark1001-5000 Employees

We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM  experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com.  
Disclaimer: http://bit.ly/GENDisclaimer

Section iconCompany Overview

Phone number
Website
genmab.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
GMAB
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
1001-5000

Section iconFunding & Financials

  • $5.5B

    Genmab has raised a total of $5.5B of funding over 6 rounds. Their latest funding round was raised on Sep 29, 2025 in the amount of $5.5B.

  • $10B

    Genmab's revenue is estimated to be in the range of $10B

Section iconFunding & Financials

  • $5.5B

    Genmab has raised a total of $5.5B of funding over 6 rounds. Their latest funding round was raised on Sep 29, 2025 in the amount of $5.5B.

  • $10B

    Genmab's revenue is estimated to be in the range of $10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.